Mineralys TherapeuticsMLYS +2.19%35 Quick Ratio is 44.33 as of Mar. 2026, which is 145% above its 10-year median of 18.06. GuruFocus rates MLYS with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Mineralys Therapeutics ranks better than 98.24% on this metric.
Mineralys Therapeutics has a quick ratio of 44.33. It generally indicates good short-term financial strength.
The historical rank and industry rank for Mineralys Therapeutics's Quick Ratio or its related term are showing as below:
MLYS'
s Quick Ratio Range Over the Past 10 Years
Min: 0.29 Med: 18.06 Max: 44.33
Current: 44.33
During the past 6 years, Mineralys Therapeutics's highest Quick Ratio was 44.33. The lowest was 0.29. And the median was 18.06.
MLYS's Quick Ratio is ranked better than 98.24% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs MLYS: 44.33
Mineralys Therapeutics (NAS:MLYS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Mineralys Therapeutics Quick Ratio Related Terms
Mineralys Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mineralys Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mineralys Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Mineralys Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Mineralys Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mineralys Therapeutics (MLYS) has a Quick Ratio of 44.33 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Mineralys Therapeutics and its competitors. This is 145% above median its historical median of 18.06. Over the past decade, Mineralys Therapeutics' Quick Ratio has ranged from 0.29 to 44.33. According to the industry distribution chart, Mineralys Therapeutics ranks #25 out of 1417 companies in the Biotechnology industry, placing it in the top 1.8%.
Is Mineralys Therapeutics' Quick Ratio too high?
Mineralys Therapeutics' current Quick Ratio of 44.33 is 145% above median its 10-year median of 18.06. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 44.33. The Biotechnology industry median Quick Ratio is 3.60. Mineralys Therapeutics' value of 44.33 is 1131.4% above this industry median. Based on the distribution chart, Mineralys Therapeutics ranks #25 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mineralys Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Quick Ratio compare to IDYA and DFTX?
According to the Biotechnology industry distribution chart, Mineralys Therapeutics ranks #25 out of 1417 companies for Quick Ratio. This places Mineralys Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Mineralys Therapeutics' value of 44.33 is 1131.4% above this benchmark. Historically, Mineralys Therapeutics' own Quick Ratio has ranged from 0.29 to 44.33 over the past decade. While the company's 10-year median is 18.06 vs. the industry median of 3.60, Mineralys Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mineralys Therapeutics's current Quick Ratio of 44.33 is 1131.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Mineralys Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mineralys Therapeutics's current Quick Ratio is 44.33, which is 145% above median its own 10-year median of 18.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Quick Ratio of 44.33. The current Quick Ratio is 44.33, which is 145% above median its 10-year median of 18.06 and 1131.4% above the Biotechnology industry median of 3.60. Mineralys Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Quick Ratio is 44.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
35GF Score
Get the complete analysis for MLYS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLYS has been successfully added to your 
